Patents by Inventor Guerard W. Byrne
Guerard W. Byrne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220062393Abstract: This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine ?1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous ?-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.Type: ApplicationFiled: August 27, 2021Publication date: March 3, 2022Applicant: Mayo Foundation for Medical Education and ResearchInventors: Guerard W. Byrne, Christopher G.A. McGregor
-
Patent number: 11141470Abstract: This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine ?1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous ?-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.Type: GrantFiled: April 24, 2017Date of Patent: October 12, 2021Assignee: Mayo Foundation for Medical Education and ResearchInventors: Christopher G. A. McGregor, Guerard W. Byrne
-
Publication number: 20170360906Abstract: This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine ?1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous ?-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.Type: ApplicationFiled: April 24, 2017Publication date: December 21, 2017Applicant: Mayo Foundation for Medical Education and ResearchInventors: Christopher G.A. McGregor, Guerard W. Byrne
-
Patent number: 9642899Abstract: This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine ?1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous ?-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.Type: GrantFiled: April 11, 2011Date of Patent: May 9, 2017Assignee: Mayo Foundation for Medical Education and ResearchInventors: Christopher G. A. McGregor, Guerard W. Byrne
-
Patent number: 9006510Abstract: A method for producing a heart valve xenograft from bovine tissue expressing reduced or undetectable levels of I1-3 galactosyl transferase are provided.Type: GrantFiled: June 12, 2007Date of Patent: April 14, 2015Assignee: Mayo Foundation for Medical Education and ResearchInventors: Guerard W. Byrne, Christopher G. A. McGregor
-
Publication number: 20130111614Abstract: This document provides methods and materials involved in reducing cardiac xenograft rejection. For example, methods and materials for preparing transgenic pigs expressing reduced or no endogenous Sda or SDa-like glycans derived from the porcine ?1,4 N-acetyl-galactosaminyl transferase 2 (B4GALNT2) glycosyltransferase and/or reduced or no endogenous ?-Gal antigens, methods and materials for modifying the xenograft recipient's immunological response to non-Gal antigens (e.g. CD46, CD59, CD9, PROCR, and ANXA2) to reduce cardiac xenograft rejection, and methods and materials for monitoring the progress of xenotransplant immunologic rejection are provided.Type: ApplicationFiled: April 11, 2011Publication date: May 2, 2013Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Christopher G.A. McGregor, Guerard W. Byrne
-
Publication number: 20090043383Abstract: The invention relates to heart valve xenografts from transgenic pigs having a disruption of an ?1-3 galactosyl transferase nucleic acid sequence and use of the xenografts for treating a patient.Type: ApplicationFiled: March 28, 2005Publication date: February 12, 2009Applicant: MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCHInventors: Christopher G.A. McGregor, Guerard W. Byrne, William R. Davies, John S. Logan
-
Publication number: 20080124396Abstract: One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (“xenoreactive antibodies” or “XNA”) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e.g., able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.Type: ApplicationFiled: October 31, 2007Publication date: May 29, 2008Applicant: Mayo Foundation for Medical Education and ResearchInventors: Alexander Schwarz, Guerard W. Byrne, Thomas A. Davis, Lisa E. Diamond, John S. Logan
-
Publication number: 20040141944Abstract: One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (“xenoreactive antibodies” or “XNA”) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e.g., able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.Type: ApplicationFiled: March 28, 2003Publication date: July 22, 2004Inventors: Alexander Schwarz, Guerard W. Byrne, Thomas A. Davis, Lisa E. Diamond, John S. Logan
-
Patent number: 6572867Abstract: One aspect of the present invention relates to methods and compositions for attenuating xenograft rejection by administering, to an animal receiving the xenograft, an amount of a polymer-derivatized xenoantigen (hereinafter “xenopolymer”) effective for inhibiting or lessening the severity of hyperacute rejection response (HAR), or other immunological response to the graft, that is dependent on the presence of the xenoantigen on the grafted tissues or cells. In certain embodiments, the xenopolymer is administered in an amount sufficient to neutralize host antibodies (“xenoreactive antibodies” or “XNA”) immunoreactive with the xenoantigen. The xenopolymer may additionally, or alternatively, be used as a tolerogen (or anergen) for the xenoantigen, e.g., able to suppress, to some degree, the production/secretion of XNAs by the immune system of the host.Type: GrantFiled: April 15, 1999Date of Patent: June 3, 2003Assignee: Baxter International Inc.Inventors: Alexander Schwarz, Guerard W. Byrne, Thomas A. Davis, Lisa E. Diamond, John S. Logan
-
Patent number: 5221778Abstract: A transgenic mouse offspring produced by the mating of a first transgenic mouse carrying a transresponder transgene whose expression is regulated by a viral gene product of HSV-1 and a second transgenic mouse carrying a transactivator transgene. A process for expressing a gene of interest which comprises the mating of a first transgenic mouse carrying a transresponder transgene whose expression is regulated by a viral gene product of HSV-1 and a second transgenic mouse carrying a transactivator transgene.Type: GrantFiled: August 24, 1988Date of Patent: June 22, 1993Assignee: Yale UniversityInventors: Guerard W. Byrne, Frank H. Ruddle